Inevitable competition between multinational and domestic pharmaceutical companies in the KRW 400 billion NSAIDs market
In the KRW 400 billion NSAIDs (non-steroidal anti-inflammatory drugs) market, the ‘2nd’ severe competition is expected among domestic and multinational pharmaceutical companies. .
First and foremost, among domestic pharmaceutical companies, Daewon Pharm has started the phenomenon by opening the ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
